Responsible Use of Oral Corticosteroids in People with Comorbid Diabetes: An Expert Consensus

• Published in: Journal of the Association of Physicians of India Vol. 72; no. 7; p. 79
• Main Authors: Saboo, Banshi, Joshi, Shashank, Gupta, Amit, Maheshwari, Anuj, Saboo, Bharat, Makkar, Brij Mohan, Bantwal, Ganapathi, Kesavadev, Jothydev, Sreenivasamurthy, L, Tiwaskar, Mangesh, Chawla, Manoj, Shunmugavelu, Minakshisundaram, Singh, Nagendra Kumar, Jethwani, Pratap, Agarwal, Sanjay, Gupta, Sunil, Swarnakar, Rajesh, Sahay, Rakesh, Vishwanathan, Vijay, Prajapati, Charmy, Qamra, Amit, Muralidharan, Parthasarathy
• Format: Journal Article
• Language: English
• Published: India 01.07.2024
• Subjects: Administration, Oral; Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - adverse effects; Comorbidity; Consensus; Diabetes Complications; Diabetes Mellitus - drug therapy; Diabetes Mellitus - epidemiology; Humans
• ISSN: 0004-5772
• DOI: 10.59556/japi.72.0573

Globally, diabetes mellitus (DM) is a substantial contributor to morbidity and mortality. Comorbidities and intercurrent illnesses in people with diabetes may necessitate the use of steroids. Acute as well as chronic use of steroids contributes substantially to the development of various complications. Despite this, there are no standard guidelines or consensus to provide a unified approach for the rational use of steroids in people with diabetes. Also, there is scant harmonization among clinicians with the use of different steroids in routine practice. To address the inconsistencies in this clinical arena, the consensus working group (CWG) formulated a unified consensus for steroid use in people with diabetes. In people with diabetes, the use of steroids causes hyperglycemia and may precipitate diabetic ketoacidosis (DKA). An increase in weight is directly related to the dose and duration of the steroid therapy. Steroid-related alterations in hyperglycemia, dyslipidemia, and hypertension (HTN) add to the increased risk of cardiovascular (CV) disease. The risk of complications such as infections, osteoporosis, myopathy, acne, cataracts, and glaucoma may increase with the use of steroids. Appropriate and timely monitoring of these complications is necessary for early detection and treatment of such complications. Given the systemic effects of various antihyperglycemic drugs, there is a possibility of aggravating or diminishing the specific complications. Preference to a safer steroid is required matching the steroid dose equivalence and individualizing patient management. In conclusion, short-, intermediate-, or long-term use of steroids in people with diabetes demands their rational use and holistic approach to identify, monitor, and treat the complications induced or aggravated by the steroids.